Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125


Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.

Vitale FV, Malaponte E, Calì S, Antonelli G, Panebianco V, Blandino R, Ferraù F.

J Oncol Pharm Pract. 2013 Sep;19(3):202-7. doi: 10.1177/1078155212458133. Epub 2012 Oct 3.


Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.

Socinski MA, Sandler AB, Israel VK, Gillenwater HH, Miller LL, Locker PK, Antonellini A, Elfring GL, Natale RB.

Cancer. 2002 Oct 1;95(7):1520-7.


Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.

Murren JR, Andersen N, Psyrri D, Brandt D, Nadkarni R, Rose M, Davies MJ, Parisot N, Rosenfield AT, Pizzorno G, Zelterman D.

Cancer Biol Ther. 2005 Dec;4(12):1311-5. Epub 2005 Dec 12.


Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.

Paccagnella A, Favaretto A, Oniga F, Festi G, Lauro S, Morabito A, Ossana L, Sartore F, DePoli F, Fiorentino MV.

Cancer. 1996 Oct 15;78(8):1701-7.


Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.

Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, Shyr Y, Carbone DP, Devore RF.

Clin Cancer Res. 2001 Jan;7(1):68-73.


Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.

Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R, Saito H.

Cancer Chemother Pharmacol. 2003 Jul;52(1):73-8. Epub 2003 May 16.


Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.

Han JY, Lee DH, Lee SY, Park CG, Kim HY, Lee HG, Lee JJ, Kim HT, Lee JS.

Cancer. 2005 Dec 15;104(12):2759-65.


Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.

Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M; Okayama Lung Cancer Study Group.

J Thorac Oncol. 2007 Jan;2(1):44-50.


Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.

Kim HS, Kim JH, Kim B, Choi HC, Kwon JH, Choi DR.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1591-7. doi: 10.1007/s00280-013-2159-0. Epub 2013 Apr 9.


Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.

Comella P, Biglietto M, Casaretti R, De Lucia L, Avallone A, Maiorino L, Di Lullo L, De Cataldis G, Rivellini F, Comella G.

Oncology. 2001;60(2):127-33.


Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma.

Hejna M, Kornek GV, Raderer M, Marosi L, Schneeweiss B, Greul R, Weinländer G, Valencak J, Huber H, Scheithauer W.

Oncology. 1998 Nov-Dec;55(6):538-42.


Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.

Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K.

Cancer Chemother Pharmacol. 2009 Oct;64(5):917-24. doi: 10.1007/s00280-009-0943-7. Epub 2009 Feb 17.


Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.

Wibmer T, Kropf C, Merk T, Schumann C, Hombach V, Krüger S.

Lung Cancer. 2008 May;60(2):231-9. Epub 2007 Nov 19.


Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

Scheithauer W, Kornek GV, Brugger S, Ullrich-Pur H, Valencak J, Raderer M, Fiebiger W, Kovats E, Lang F, Depisch D.

Cancer Invest. 2002;20(1):60-8.


The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.

Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS.

Cancer. 2002 Jul 15;95(2):340-53. Erratum in: Cancer. 2003 Mar 1;97(5):1367.


A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.

Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP.

Cancer Chemother Pharmacol. 2007 Jan;59(1):51-9. Epub 2006 Apr 19.


A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.

Kakolyris S, Souglakos J, Agelaki S, Kourousis CH, Mavroudis D, Sarra E, Malliotakis P, Georgoulias V.

Lung Cancer. 2000 Dec;30(3):193-8.


Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM.

J Thorac Oncol. 2008 Jan;3(1):59-67. doi: 10.1097/JTO.0b013e31815e8566.


Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.

Fukuda M, Soda H, Fukuda M, Kinoshita A, Nakamura Y, Nagashima S, Takatani H, Tsukamoto K, Kohno S, Oka M.

Cancer. 2007 Aug 1;110(3):606-13.

Supplemental Content

Support Center